Ricevi le ultime notizie sulle azioni Candel Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di CADL

Ultime notizie per

CANDEL THERAPEUTICS INC

Candel Therapeutics

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics Inc

Cadeler AS

News

Financing

Press Releases

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

General

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Health Care

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Earnings

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

CADL

Abeona Therapeutics

AC Immune

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Annexon

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Jade Biosciences

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lyell Immunopharma

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Neurogene

Puma Biotechnology

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Zura Bio Limited - Class A Ordinary shares

Zura Bio

HC Wainwright & Co.

B of A Securities

Canaccord Genuity

Screenshot 2024-06-13 at 5.29.56 PM

Biotech

Candel Therapeutics&#39; (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Screenshot 2024-06-06 at 5.30.54 PM

Candel Therapeutics&#39; (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Screenshot 2024-05-31 at 5.22.29 PM

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Screenshot 2024-04-04 at 9.54.11 PM

Chief Science Officer Talks Innovation In Cancer Research

Screenshot 2024-03-25 at 6.13.53 PM

The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research

Screenshot 2024-03-14 at 5.26.26 PM

Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors

Screenshot 2024-03-05 at 6.31.45 PM

CGON

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-27 at 6.29.08 PM

Moving Fast: Candel&#39;s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

Comments

Candel Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO